"The antibodies have now been successfully tested for performance, allowing the reagents to be configured into the immunoassay test kit, also known as an ELISA (enzyme linked immunosorbent assay), that can be used in clinical laboratories around the world."
Most interestingly is the updated timetable for PIQ ..... there are two licensing deals still
scheduled in December and another in Febuary....
PIQ is progressing..... and the hiring of two new Board members who have commercialisation
experience at a time when activity is increasing would seem to be justified...
All IMO.........GLTA
PIQ Price at posting:
18.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)